Tolinapant is under clinical development by Taiho Pharmaceutical and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tolinapant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tolinapant overview
Tolinapant (ASTX-660) (AT-IAP) is under development for the treatment of solid tumors, lymphomas such as diffuse large B-cell lymphoma, extranodal natural killer (NK)/T-cell lymphoma nasal type, triple negative breast cancer (TNBC), human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), cholangiocarcinoma, pancreatic cancer, hepatocellular cancer, cervical cancer, glioblastoma, recurrent head, and neck squamous cell carcinoma, laryngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, nasopharyngeal cancer, breast cancer, relapsed or refractory peripheral T-cell lymphoma (PTCL), relapsed or refractory cutaneous T-cell lymphoma (CTCL), relapsed or refractory adult T-cell leukemia/lymphoma (ATLL), angioimmunoblastic T-cell lymphoma, anaplastic large-cell lymphoma (ALCL), melanoma and epithelial ovarian, fallopian tube and primary peritoneal cancer. The drug candidate is administered through the oral route. It is a dual antagonist of XIAP and cIAP1. The drug is developed based on Pyramid technology. It was also under development for the treatment of leukemia, relapsed and refractory (R/R) acute myeloid leukemia.
Taiho Pharmaceutical overview
Taiho Pharmaceutical (Taiho), a subsidiary of Otsuka Group, is a global pharmaceutical company primarily engaged in the research, development, and supply of pharmaceutical products. The company’s main activities include the development of innovative drugs, particularly in the areas of oncology and immune-related diseases. Taiho’s major products include a range of prescription drugs, such as Lonsurf and other consumer healthcare products. The company serves a broad customer base, including patients, healthcare professionals, and medical staff, providing solutions for various health conditions and diseases. The company’s products are available worldwide. Taiho operates globally, with business locations in the US, Europe, Asia, and Oceania. Taiho is headquartered in Tokyo, Japan.
For a complete picture of Tolinapant’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
